99 studies found for:    autoinflammatory
Show Display Options
Rank Status Study
21 Completed Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients
Conditions: Cryopyrin-associated Periodic Syndromes (CAPS);   Familial Cold Autoinflam Syn (FCAS);   Muckle-wells Syn (MWS);   Neonatal Onset Multisystem Inflam Disease (NOMID)
Intervention:
22 Completed The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada
Condition: Cryopyrin Associated Periodic Syndrome
Intervention: Drug: canakinumab (company code: ACZ885D)
23 Recruiting Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
Conditions: Rheumatoid Arthritis;   Ankylosing Spondylitis;   Systemic Lupus Erythematosus;   Psoriasis;   Behcet's Disease;   Wegener's Granulomatosis;   Takayasu's Disease;   Crohn's Disease;   Ulcerative Colitis;   Autoimmune Hepatitis;   Sclerosing Cholangitis
Intervention: Drug: Interleukin 2
24 Recruiting Chronic Non-bacterial Osteomyelitis Treated With Pamidronate
Conditions: Immune System Disease;   Musculoskeletal Disease
Interventions: Drug: Pamidronatdinatrium;   Other: Natrium chloride 9mg/ml
25 Recruiting Genetic and Functional Analysis of Cherubism
Condition: Cherubism
Intervention:
26 Active, not recruiting Ilaris® Effects in Schnitzler Syndrome (ILESCH)
Condition: Schnitzler Syndrome
Interventions: Drug: Canakinumab;   Drug: Placebo
27 Unknown  Canakinumab for Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Intervention: Drug: Canakinumab
28 Completed Ilaris (Canakinumab) in the Schnitzler Syndrome
Condition: Schnitzler Syndrome
Intervention: Drug: Ilaris
29 Withdrawn An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
Condition: Systemic Juvenile Idiopathic Arthritis
Interventions: Drug: ACZ885;   Drug: Canakinumab
30 Unknown  Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Factors
Condition: Schnitzler Syndrome
Intervention:
31 Completed The Rifaximin Study in CVID
Condition: Common Variable Immunodeficiency (CVID)
Intervention: Drug: Rifaximin
32 Recruiting Life Quality Study for PFAPA Patient
Condition: PFAPA Syndrome
Intervention: Other: Quality of life
33 Completed AnakInRa for Treatment of Recurrent Idiopathic Pericarditis (AIRTRIP)
Condition: Idiopathic Recurrent Pericarditis
Interventions: Drug: Anakinra;   Drug: Placebo
34 Completed the Influence of Remote Ischemic Preconditioning on Inflammation During Human Endotoxemia
Conditions: Autoimmune Diseases;   Infection
Interventions: Other: Multiple-dose Remote Ischemic Preconditioning;   Other: Single-dose Remote Ischemic Preconditioning;   Biological: LPS infusion
35 Completed Efficacy and Safety of Canakinumab in Schnitzler Syndrome
Condition: Schnitzler Syndrome
Intervention: Drug: Canakinumab
36 Recruiting Anakinra for Inflammatory Pustular Skin Diseases
Condition: Pustular Dermatosis
Intervention: Drug: Anakinra
37 Recruiting Cold Contact Urticaria Treatment With Rilonacept
Condition: Cold Contact Urticaria
Interventions: Drug: Rilonacept;   Drug: Placebo
38 Not yet recruiting H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults
Conditions: Avian Influenza;   Influenza
Interventions: Drug: AS03;   Drug: MF59;   Biological: Monovalent Influenza A/H5N8 vaccine
39 Completed The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With FMF
Condition: Familial Mediterranean Fever
Intervention: Drug: colchicine
40 Enrolling by invitation Controlled Ceasing of Colchicine Therapy in Familial Mediterranean Fever (FMF) Patients With Single MEFV (Mediterranean Fever) Gene Mutation
Condition: Familial Mediterranean Fever
Intervention: Other: Colchicine Cessation

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years